Mixed results for AstraZeneca in Scotland while patient access scheme swings yes for Pfizer
This article was originally published in Scrip
Executive Summary
There was mixed news for AstraZeneca in Scotland after the country's health technology appraisal body, the Scottish Medicines Consortium, turned down Seroquel (quetiapine) for major depressive episodes in bipolar disorder but accepted Brillique (ticagrelor)for atherothrombotic events in adult with acute coronary syndromes. Meanwhile, a patient access scheme helped Pfizer secure a yes for its Sutent (sunitinib).
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.